In brief
Amy Abernethy argues that healthcare innovation only reaches patients if every stage of the pipeline speeds up together, including discovery, clinical trials, regulatory review and rollout. Regulators can keep pace with AI only by working closely with innovators early, regulating AI in reusable pieces, and using automation and AI themselves.
The central tension is a fast-growing flood of AI products heading into a regulatory system that has not changed much. Abernethy says adding more reviewers is not enough. Her answer is shared definitions of what counts as credible evidence, earlier regulator familiarity, and smarter, risk-targeted oversight. She notes that the FDA's January 2021 AI action plan had not yet become new rules.
Questions
Why did COVID vaccines get stuck even though the science was fast?
Abernethy says the vaccines were developed very quickly, but proving who they worked for relied on clinical trial methods from roughly 1995. The slow stages after discovery created a bottleneck.
What was the Evidence Accelerator?
It was a forum Abernethy describes where the FDA and innovators met closely to test new kinds of evidence, especially real-world data. Regulators could say what they trusted, and innovators could show what they were doing.
Does the FDA already regulate AI medical products?
Abernethy says AI-based devices are already regulated under the traditional device framework, such as diagnostics or software as a medical device. The harder problems are the sheer volume of products and algorithms that keep learning over time.
How could AI make drug and device regulation faster?
She suggests automating parts of the review, having companies send data directly to the FDA, and regulating a base AI model once so only the specialized layer on top needs checking. She also suggests using AI to target oversight where risk is highest.
What is Verily trying to build, according to Abernethy?
Verily aims to unlock precision health for everyone by building a data bridge between research and care. That means software for clinical trials and for managing conditions like diabetes, connected through curated data that can also be used to build and check AI models.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
Amy Abernethy says the COVID-19 genome was sequenced and published for scientists worldwide within 24 hours, which enabled rapid mRNA vaccine development.
“essentially sequencing the genome, publishing it for scientists all around the world to use within 24 hours, and then moving from there.”
0:03:04 · Amy Abernethy · COVID genome
Amy Abernethy says that testing the mRNA vaccines used clinical trial methods from around 1995, with little innovation in trial design.
“we hit the wall of evidence generation where we went back to circa 1995 clinical trials to actually try and understand which of the mRNA vaccines worked for whom and when.”
0:03:04 · Amy Abernethy · Clinical trials · 1995
Amy Abernethy says data from Israel's health systems was used to study how long COVID-19 vaccine effectiveness lasts, safety signals and the need for boosters.
“we leveraged, for example, data from the Israel health systems to understand duration of effectiveness and safety signals and do you need a booster.”
0:03:35 · Amy Abernethy · Vaccine data
Amy Abernethy says the Evidence Accelerator brought the FDA and innovators together so regulators could say which evidence they trusted and what they wanted to know more about.
“We called this the evidence accelerator. And regulators and others could say, I trust this, I don't trust that, here's what I want to know more about.”
0:07:13 · Amy Abernethy · Evidence Accelerator
Amy Abernethy says Friends of Cancer Research spread real-world data thinking across the industry so that many innovators, not one company, could contribute.
“Friends of Cancer Research promulgated that thinking across the industry so that it wasn't just any one company, but rather all innovators having the chance to say what they thought.”
0:10:56 · Amy Abernethy · Industry convening
Amy Abernethy says the FDA issued three core guidances on real-world data at the end of 2021, informed by the collaborative process she described.
“That then informed the guidance that came out from FDA at the end of 2021. There were three core guidances around robot data, all informed by that process.”
0:11:30 · Amy Abernethy · FDA guidance · 2021
Amy Abernethy says using AI to identify drug targets creates little regulatory worry because the work happens before a molecule is put into people.
“there's some parts of the application of AI in the healthcare and life sciences landscape that don't really create a bunch of angst. Identification of targets is a good example of that.”
0:13:36 · Amy Abernethy · AI drug discovery
Amy Abernethy says her first real job, in 1982, was in an artificial intelligence lab at NASA.
“That was where my first real job was in 1982. And so that's a long time ago.”
0:16:11 · Amy Abernethy · Career history · 1982
Amy Abernethy says the visible surge in artificial intelligence development happened at the end of 2022.
“the pace of development in artificial intelligence ultimately happened at the end of 2022”
0:15:39 · Amy Abernethy · AI timeline · 2022
Amy Abernethy says AI-based products can be regulated under the FDA's traditional device framework, such as diagnostics or software as a medical device.
“We can regulate them according to the traditional device framework, whether that's a diagnostic or a software as a medical device.”
0:18:08 · Amy Abernethy · Device regulation
Amy Abernethy says the FDA published an action plan for AI-based medical software around January 2021.
“And I think it was like around January 2021, put out an action plan to specify, here are the details of what we think good's going to look like in this space.”
0:19:11 · Amy Abernethy · FDA AI plan · 2021
Amy Abernethy says the FDA's AI action plan called for good software design and an easy way to understand an AI product's output.
“We need, you know, good software design. We need to make sure that there is an easy way to understand the output of an AI-based product”
0:19:11 · Amy Abernethy · FDA AI plan · 2021
Amy Abernethy says the FDA's AI action plan also called for validation testing and performance monitoring over time.
“we need appropriate validation testing and we need some mechanism for performance monitoring across time.”
0:19:11 · Amy Abernethy · AI monitoring · 2021
Amy Abernethy says that, as far as she knew, the FDA's AI action plan had not been turned into a new rule set.
“that actually hasn't translated to a new rule set, as far as I know, beyond what we've previously had.”
0:19:45 · Amy Abernethy · FDA rules
Amy Abernethy says companies traditionally submit clinical trial results to the FDA as hundreds of pages of reports and then wait for questions.
“you ultimately package up the clinical trial, write hundreds of pages of reports, and ultimately ship that over the FDA and wait for questions to come back.”
0:20:47 · Amy Abernethy · FDA submissions
Amy Abernethy says that while at the FDA she worked on infrastructure so companies could push data directly to the agency instead of submitting lengthy reports.
“we were building the pipes at FDA to be ready for a landscape where really all you do is push your data across over FDA and FDA is ready to receive”
0:21:23 · Amy Abernethy · FDA data pipes
Amy Abernethy proposes that a foundation model for reading chest X-rays could be regulated once, so specialized models built on it need less review.
“a foundational model of reading a chest X-ray. And then that's already done, a check for the foundational model.”
0:21:52 · Amy Abernethy · Foundation models
Amy Abernethy says statistical programs written 10 to 15 years ago began targeting clinical trial monitors' work at higher-risk sites, which became risk-based monitoring.
“pattern recognition and statistical programs were written about 10, 15 years ago to start to do that and better target the work of monitors.”
0:25:37 · Amy Abernethy · Risk-based monitoring
Amy Abernethy says Verily's goal is to unlock the promise of precision health for everyone every day.
“our goal is to unlock the promise of precision health for everyone every day.”
0:26:33 · Amy Abernethy · Verily mission
Amy Abernethy says Verily builds software for clinical research sites, clinical trials and patient recruitment, plus products in healthcare delivery such as diabetes management.
“software for clinical research sites, software to conduct clinical trials, patient recruitment, as well as products in the healthcare delivery ecosystem”
0:27:01 · Amy Abernethy · Verily products